Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Headache Recurrence and Treatment.

Literature DB >> 12162921

Headache Recurrence and Treatment.

Abstract

The definition of recurrence includes the following: any headache occurring after a headache-free state at 2 hours and within 24 hours after intake of drug; a headache that has never been studied systematically; a headache that may not be an outcome of drug treatment; a headache that may be due to the inherent nature of migraine and individual patient characteristics such as duration of attack; and headache for which effective treatment may be a re-dose of the initial medication or addition of steroidal or nonsteroidal anti-inflammatory medications.

Entities: Disease Species

Year: 2002 PMID： 12162921 DOI： 10.1007/s11940-002-0043-z

Source DB: PubMed Journal: Curr Treat Options Neurol ISSN： 1092-8480 Impact factor: 3.598

31 in total

1. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan.

Authors: V Pfaffenrath; G Cunin; G Sjonell; S Prendergast
Journal: Headache Date: 1998-03 Impact factor: 5.887

2. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.

Authors: E L Spierings; B Gomez-Mancilla; D E Grosz; C R Rowland; F S Whaley; K J Jirgens
Journal: Arch Neurol Date: 2001-06

3. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug.

Authors: A V Krymchantowski; J S Barbosa
Journal: Arq Neuropsiquiatr Date: 2001-09 Impact factor: 1.420

4. Brain stem activation in spontaneous human migraine attacks.

Authors: C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal: Nat Med Date: 1995-07 Impact factor: 53.440

5. Tolfenamic acid decreases migraine recurrence when used with sumatriptan.

Authors: A V Krymchantowski; M Adriano; D Fernandes
Journal: Cephalalgia Date: 1999-04 Impact factor: 6.292

6. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.

Authors: S P Ahrens; M V Farmer; D L Williams; E Willoughby; K Jiang; G A Block; W H Visser
Journal: Cephalalgia Date: 1999-06 Impact factor: 6.292

7. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.

Authors: A Klassen; A Elkind; M Asgharnejad; C Webster; A Laurenza
Journal: Headache Date: 1997 Nov-Dec Impact factor: 5.887

Headache Recurrence and Treatment.

1. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan.

2. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.

3. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug.

4. Brain stem activation in spontaneous human migraine attacks.

5. Tolfenamic acid decreases migraine recurrence when used with sumatriptan.

6. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.

7. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.

8. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.

9. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan.

10. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients.

Review 1. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.

Review 2. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment.